<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01122251</url>
  </required_header>
  <id_info>
    <org_study_id>LG-ZVCL001</org_study_id>
    <nct_id>NCT01122251</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension</brief_title>
  <official_title>A Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy Phase II Trial to Evaluate the Efficacy and Safety of the Combinations of Lercanidipine and Valsartan in Comparison to Each Component Administered Alone and to Determine the Optimal Dose Combinations in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of fixed combination of
      lercanidipine (10 mg or 20 mg) and valsartan (80 mg or 160 mg), lercanidipine and valsartan
      alone in reducing blood pressure. The study will investigate the dose response relationship
      for the combinations and monotherapies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sitDBP</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Average changes from baseline in sitDBP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sitDBP</measure>
    <time_frame>Week 4, 8</time_frame>
    <description>Response rates (proportion of patients sitDBP&lt;90mmHg or ≥10-mmHg reduction from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sitDBP</measure>
    <time_frame>Week 4</time_frame>
    <description>Average changes from baselin in sitDBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sitSBP</measure>
    <time_frame>Week 4, 8</time_frame>
    <description>Average changes from baselini in sitSBP</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">441</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Lercanidpine + Valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>L10/V80, L20/V80, L10/V160, L20/V160</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lercanidipine or Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>L10, L20, V80, V160</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparators of Lercanidipine and Valsartan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lercanidipine + Valsartan</intervention_name>
    <description>L10/V80, L20/V80, L10/V160, L20/V160</description>
    <arm_group_label>Lercanidpine + Valsartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lercanidipine or Valsartan</intervention_name>
    <description>L10, L20, V80, V160</description>
    <arm_group_label>Lercanidipine or Valsartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of Lercanidipine and Valsartan</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged between 20 and 75

          -  Essential hypertension at screening (-3 week)

        Randomization Criteria:

          -  Essential hypertension at baseline (90mmHg≤sitDBP≤109mmHg, except sitSBP≥180)

        Exclusion Criteria:

          -  Mean sitDBP≥110mmHg or sitSBP≥180

          -  Secondary hypertension or suspected secondary hypertension

          -  Uncontrolled diabetes

          -  Severe heart disease or severe cerebrovascular disease

          -  clinically significant hematological test results, renal disease (serum creatinine) or
             liver disease (ALT or AST)

          -  History of malignant disease

          -  Autoimmune disease

          -  Women with a positive pregnancy test result, breast feeding or intention of pregnancy
             during the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>23 sites in Korea</name>
      <address>
        <city>Seoul, Busan etc.</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/highbloodpressure.html</url>
    <description>High Blood Pressure</description>
  </link>
  <link>
    <url>http://www.mims.co.uk/Drugs/cardiovascular-system/hypertension/zanidip/</url>
    <description>Lercanidipine</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=0137862534&amp;QV1=VALSARTAN</url>
    <description>Valsartan</description>
  </link>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2010</study_first_submitted>
  <study_first_submitted_qc>May 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2010</study_first_posted>
  <last_update_submitted>February 17, 2011</last_update_submitted>
  <last_update_submitted_qc>February 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Kim, Sung Il / Assistant Manager</name_title>
    <organization>Clinical Trial 1 Team</organization>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>lercanidipine</keyword>
  <keyword>valsartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lercanidipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

